SG11202011969WA - Methods for characterizing protein complexes - Google Patents
Methods for characterizing protein complexesInfo
- Publication number
- SG11202011969WA SG11202011969WA SG11202011969WA SG11202011969WA SG11202011969WA SG 11202011969W A SG11202011969W A SG 11202011969WA SG 11202011969W A SG11202011969W A SG 11202011969WA SG 11202011969W A SG11202011969W A SG 11202011969WA SG 11202011969W A SG11202011969W A SG 11202011969WA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- protein complexes
- characterizing protein
- characterizing
- complexes
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
- G01N21/49—Scattering, i.e. diffuse reflection within a body or fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/0005—Field flow fractionation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Footwear And Its Accessory, Manufacturing Method And Apparatuses (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862724700P | 2018-08-30 | 2018-08-30 | |
PCT/US2019/048526 WO2020047067A1 (en) | 2018-08-30 | 2019-08-28 | Methods for characterizing protein complexes |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202011969WA true SG11202011969WA (en) | 2020-12-30 |
Family
ID=68063024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202011969WA SG11202011969WA (en) | 2018-08-30 | 2019-08-28 | Methods for characterizing protein complexes |
Country Status (15)
Country | Link |
---|---|
US (2) | US11754569B2 (en) |
EP (1) | EP3775926A1 (en) |
JP (1) | JP7511542B2 (en) |
KR (1) | KR20210053816A (en) |
CN (1) | CN112601963B (en) |
AU (1) | AU2019333047A1 (en) |
BR (1) | BR112020026348A2 (en) |
CA (1) | CA3100038A1 (en) |
EA (1) | EA202190032A1 (en) |
IL (1) | IL280884A (en) |
MX (1) | MX2021002281A (en) |
SG (1) | SG11202011969WA (en) |
TW (1) | TW202024639A (en) |
WO (1) | WO2020047067A1 (en) |
ZA (1) | ZA202007067B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210040197A1 (en) | 2019-08-08 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Novel antigen binding molecule formats |
WO2023004282A2 (en) | 2021-07-19 | 2023-01-26 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
WO2023086812A1 (en) | 2021-11-11 | 2023-05-19 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
CN114874349B (en) * | 2022-06-15 | 2023-03-10 | 河北大学 | Method for separating and purifying ganoderan based on field flow separation technology |
US20240167984A1 (en) | 2022-11-18 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Methods for detecting and determining protein structures and stability in fluids, including biological fluids |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US6927004B2 (en) | 2002-03-08 | 2005-08-09 | Asml Netherlands B.V. | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
DK2374818T3 (en) | 2006-06-02 | 2013-01-21 | Regeneron Pharma | High affinity antibodies to human IL-6 receptor |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
CA2695199C (en) | 2007-07-31 | 2016-07-19 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human cd20 and method of using thereof |
US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
JO3672B1 (en) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | High Affinity Human Antibodies to PCSK9 |
KR20120027055A (en) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | Readily isolated bispecific antibodies with native immunoglobulin format |
JO3417B1 (en) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies |
US20130028920A1 (en) | 2010-03-31 | 2013-01-31 | Universite De Geneve | Stabilized antibody preparations and uses thereof |
JO3340B1 (en) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | Antibodies to human gdf8 |
US8163182B2 (en) | 2010-05-28 | 2012-04-24 | Wyatt Technology Corporation | Compartmentalized field flow fractionation |
JOP20190250A1 (en) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | Stabilized formulations containing anti-ngf antibodies |
AR083044A1 (en) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | ANTI-CD48 ANTIBODIES AND USES OF THE SAME |
EP3733711A1 (en) | 2010-10-06 | 2020-11-04 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
JO3756B1 (en) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to the glucagon receptor |
JO3412B1 (en) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | Anti-angptl3 antibodies and uses thereof |
AU2012339722B2 (en) | 2011-11-14 | 2017-09-14 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A |
WO2013112438A1 (en) | 2012-01-23 | 2013-08-01 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ang2 antibodies |
US10481164B2 (en) * | 2012-03-26 | 2019-11-19 | Amgen Inc. | Method for using light scattering in real time to directly monitor and control impurity removal in purification processes |
HUE043698T2 (en) | 2012-04-17 | 2019-09-30 | Aeneas Gmbh & Co Kg | Method for presymptomatic diagnosis of coeliac disease and gluten sensitivity |
JO3820B1 (en) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | Human antibodies to fel d1 and methods of use thereof |
TWI641619B (en) | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | Anti-egfr antibodies and uses thereof |
US9540449B2 (en) | 2012-08-13 | 2017-01-10 | Regeneron Pharmaceuticals, Inc. | Anti-PCSK9 antibodies with pH-dependent binding characteristics |
JOP20200236A1 (en) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
JO3405B1 (en) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF |
JO3532B1 (en) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | Anti-il-33 antibodies and uses thereof |
TWI659968B (en) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | Human antibodies to respiratory syncytial virus f protein and methods of use thereof |
US9637535B2 (en) | 2013-03-15 | 2017-05-02 | Regeneron Pharmaceuticals, Inc. | IL-33 antagonists and uses thereof |
TWI641620B (en) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | Anti-prlr antibodies and uses thereof |
TWI680138B (en) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
JP6632984B2 (en) | 2014-03-11 | 2020-01-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Anti-EGFRvIII antibodies and uses thereof |
TWI701042B (en) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | Methods and antibody compositions for tumor treatment |
EP3636073B1 (en) | 2014-05-05 | 2023-11-15 | Regeneron Pharmaceuticals, Inc. | Humanized c5 and c3 animals |
JO3701B1 (en) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to middle east respiratory syndrome – coronavirus spike protein |
US20160266028A1 (en) | 2014-07-18 | 2016-09-15 | Wyatt Technology Corporation | Method to measure the structure of small particles in solution |
EP3194441A1 (en) | 2014-09-16 | 2017-07-26 | Regeneron Pharmaceuticals, Inc. | Anti-glucagon antibodies and uses thereof |
TWI710573B (en) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | Human antibodies to ebola virus glycoprotein |
SG11201805579SA (en) | 2016-01-27 | 2018-08-30 | CSL Behring Lengnau AG | Recombinant igg fc multimers |
EP3724226A1 (en) * | 2017-12-13 | 2020-10-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
-
2019
- 2019-08-28 EP EP19773980.8A patent/EP3775926A1/en active Pending
- 2019-08-28 TW TW108130758A patent/TW202024639A/en unknown
- 2019-08-28 SG SG11202011969WA patent/SG11202011969WA/en unknown
- 2019-08-28 KR KR1020207037969A patent/KR20210053816A/en not_active Application Discontinuation
- 2019-08-28 US US16/553,312 patent/US11754569B2/en active Active
- 2019-08-28 JP JP2021504752A patent/JP7511542B2/en active Active
- 2019-08-28 EA EA202190032A patent/EA202190032A1/en unknown
- 2019-08-28 CA CA3100038A patent/CA3100038A1/en active Pending
- 2019-08-28 MX MX2021002281A patent/MX2021002281A/en unknown
- 2019-08-28 WO PCT/US2019/048526 patent/WO2020047067A1/en unknown
- 2019-08-28 BR BR112020026348-6A patent/BR112020026348A2/en unknown
- 2019-08-28 CN CN201980055175.3A patent/CN112601963B/en active Active
- 2019-08-28 AU AU2019333047A patent/AU2019333047A1/en active Pending
-
2020
- 2020-11-12 ZA ZA2020/07067A patent/ZA202007067B/en unknown
-
2021
- 2021-02-15 IL IL280884A patent/IL280884A/en unknown
-
2023
- 2023-07-06 US US18/218,957 patent/US20240019443A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112020026348A2 (en) | 2021-03-30 |
CN112601963B (en) | 2024-05-24 |
EP3775926A1 (en) | 2021-02-17 |
MX2021002281A (en) | 2021-05-27 |
ZA202007067B (en) | 2024-04-24 |
JP7511542B2 (en) | 2024-07-05 |
JP2021535361A (en) | 2021-12-16 |
KR20210053816A (en) | 2021-05-12 |
WO2020047067A1 (en) | 2020-03-05 |
CN112601963A (en) | 2021-04-02 |
CA3100038A1 (en) | 2020-03-05 |
EA202190032A1 (en) | 2021-03-12 |
AU2019333047A1 (en) | 2020-12-03 |
US11754569B2 (en) | 2023-09-12 |
TW202024639A (en) | 2020-07-01 |
US20200072844A1 (en) | 2020-03-05 |
IL280884A (en) | 2021-04-29 |
US20240019443A1 (en) | 2024-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281804A (en) | Protein purification methods | |
IL288613A (en) | Multispecific proteins | |
IL280884A (en) | Methods for characterizing protein complexes | |
DK3737402T3 (en) | Modificeret protein | |
IL263342A (en) | Method for stabilizing proteins | |
EP3463414C0 (en) | Protein interfaces | |
IL279355A (en) | Anti-steap1 antigen-binding protein | |
IL281088A (en) | Flt3l-based chimeric proteins | |
GB201803724D0 (en) | Methods | |
SG11202109901TA (en) | Protein binders for irhom2 | |
IL292145A (en) | Methods for characterizing host-cell proteins | |
ZA201906821B (en) | Anti-jagged1 antigen binding proteins | |
GB201708330D0 (en) | Fusion protein for enhancing intestinal regeneration | |
SG11202010335WA (en) | Techniques for performing secure operations | |
IL284317A (en) | Pseudofab-based multispecific binding proteins | |
IL258340A (en) | Quantifying met protein for cancer treatment | |
GB201802486D0 (en) | Methods | |
GB201815670D0 (en) | Protein editing | |
GB201601690D0 (en) | G proteins | |
SG11202007342QA (en) | Methods | |
GB201805466D0 (en) | Methods | |
EP3784679C0 (en) | Phosphinimine amido-ether complexes | |
ZA201901862B (en) | Modified factor h binding protein | |
GB201814451D0 (en) | Methods | |
GB201703416D0 (en) | Method for protein expression |